Mavacamten

Drug Profile

Mavacamten

Alternative Names: HCM 1; MYK-461; SAR-439152

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MyoKardia
  • Class Cardiovascular therapies; Small molecules
  • Mechanism of Action Myosin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypertrophic cardiomyopathy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 18 Sep 2017 Updated adverse events and efficacy data from the phase-II PIONEER-HCM clinical trial in Hypertrophic cardiomyopathy released by MyoKardia
  • 07 Aug 2017 Safety and efficacy data from the phase-II PIONEER-HCM clinical trial in Hypertrophic cardiomyopathy released by MyoKardia
  • 19 Jun 2017 MyoKardia plans a phase II trial for non-obstructive Hypertrophic cardiomyopathy in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top